These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 15103748)

  • 41. Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.
    Barth MJ; Czuczman MS
    Future Oncol; 2013 Dec; 9(12):1829-39. PubMed ID: 24295413
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.
    Bowen AL; Zomas A; Emmett E; Matutes E; Dyer MJ; Catovsky D
    Br J Haematol; 1997 Mar; 96(3):617-9. PubMed ID: 9054672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H).
    Galimberti S; Cervetti G; Cecconi N; Fazzi R; Pacini S; Guerrini F; Manetti C; Caracciolo F; Petrini M
    J Immunother; 2004; 27(5):389-93. PubMed ID: 15314547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro.
    Morabito F; Mangiola M; Rapezzi D; Zupo S; Oliva BM; Ferraris AM; Spriano M; Rossi E; Stelitano C; Callea V; Cutrona G; Ferrarini M
    Haematologica; 2003 Aug; 88(8):864-73. PubMed ID: 12935974
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.
    Wild J; Schmiedel BJ; Maurer A; Raab S; Prokop L; Stevanović S; Dörfel D; Schneider P; Salih HR
    Leukemia; 2015 Aug; 29(8):1676-83. PubMed ID: 25710310
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
    Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
    Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
    Lin TS; Moran M; Lucas M; Waymer S; Jefferson S; Fischer DB; Grever MR; Byrd JC
    Hematol Oncol Clin North Am; 2004 Aug; 18(4):895-913, ix-x. PubMed ID: 15325705
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
    Nguyen DD; Cao TM; Dugan K; Starcher SA; Fechter RL; Coutre SE
    Clin Lymphoma; 2002 Sep; 3(2):105-10. PubMed ID: 12435283
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Monoclonal Antibodies Campath-1H and Rituximab in theTherapy of Chronic Lymphocytic Leukemia.
    Schulz H; Winkler U; Staak JO; Engert A
    Onkologie; 2000 Dec; 23(6):526-532. PubMed ID: 11441256
    [TBL] [Abstract][Full Text] [Related]  

  • 50. State-of-the-art treatment of chronic lymphocytic leukemia.
    Hallek M
    Hematology Am Soc Hematol Educ Program; 2009; ():440-9. PubMed ID: 20008230
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Curative efficacy of fludarabine combined with rituximab and amifostine on aged patient with B-chronic lymphocytic leukemia].
    Liu Y; Zhu HL; Lu XC; Li SX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):989-92. PubMed ID: 17956676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells.
    Bogusz J; Majchrzak A; Mędra A; Cebula-Obrzut B; Robak T; Smolewski P
    Postepy Hig Med Dosw (Online); 2013 Mar; 67():107-18. PubMed ID: 23475487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.
    Byrd JC; Kitada S; Flinn IW; Aron JL; Pearson M; Lucas D; Reed JC
    Blood; 2002 Feb; 99(3):1038-43. PubMed ID: 11807010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic lymphocytic leukemia.
    Keating MJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):107-14. PubMed ID: 10561025
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
    Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
    Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
    Tam CS; O'Brien S; Lerner S; Khouri I; Ferrajoli A; Faderl S; Browning M; Tsimberidou AM; Kantarjian H; Wierda WG
    Leuk Lymphoma; 2007 Oct; 48(10):1931-9. PubMed ID: 17917961
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocytic leukemia.
    Wolowiec D; Ciszak L; Kosmaczewska A; Bocko D; Teodorowska R; Frydecka I; Kuliczkowski K
    Haematologica; 2001 Dec; 86(12):1296-304. PubMed ID: 11726322
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.
    Marquez ME; Hernández-Uzcátegui O; Cornejo A; Vargas P; Da Costa O
    Br J Haematol; 2015 Apr; 169(2):211-8. PubMed ID: 25612644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current status of monoclonal antibody therapy for chronic lymphocytic leukemia.
    Nabhan C; Dyer MJ; Rosen ST
    Oncology (Williston Park); 2003 Feb; 17(2):253-62; discussion 264, 267, passim. PubMed ID: 12632866
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.
    Mone AP; Cheney C; Banks AL; Tridandapani S; Mehter N; Guster S; Lin T; Eisenbeis CF; Young DC; Byrd JC
    Leukemia; 2006 Feb; 20(2):272-9. PubMed ID: 16341049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.